gms | German Medical Science

Deutscher Kongress für Orthopädie und Unfallchirurgie
74. Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie
96. Tagung der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie
51. Tagung des Berufsverbandes der Fachärzte für Orthopädie und Unfallchirurgie

26. - 29.10.2010, Berlin

Proliferation and differentiation of mesenchymal stromal cells from osteoarthritic donors

Meeting Abstract

  • H. Friedrich - University Hospital Carl Gustav Carus, Department of Orthopaedics, Dresden, Germany
  • C. Vater - University Hospital Carl Gustav Carus, Department of Orthopaedics, Dresden, Germany
  • J. Rauh - University Hospital Carl Gustav Carus, Department of Orthopaedics, Dresden, Germany
  • K.-P. Günther - University Hospital Carl Gustav Carus, Department of Orthopaedics, Dresden, Germany
  • C. Bünger - University Hospital of Arhus, Dept. of Orthopaedic Surgery, Aarhus C, Denmark
  • M. Stiehler - University Hospital Carl Gustav Carus, Department of Orthopaedics, Dresden, Germany

Deutscher Kongress für Orthopädie und Unfallchirurgie. 74. Jahrestagung der Deutschen Gesellschaft für Unfallchirurgie, 96. Tagung der Deutschen Gesellschaft für Orthopädie und Orthopädische Chirurgie, 51. Tagung des Berufsverbandes der Fachärzte für Orthopädie. Berlin, 26.-29.10.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. DocIN17-222

DOI: 10.3205/10dkou104, URN: urn:nbn:de:0183-10dkou1043

Published: October 21, 2010

© 2010 Friedrich et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Osteoarthritis (OA) is one of the most frequent musculoskeletal disorders and represents the main indication for total joint arthroplasty http://www.jru.orthop.gu.se/. Multipo-tent mesenchymal stromal cells (MSCs) can be easily isolated and culture expanded from bone marrow aspirates and provide an excellent source of progenitor cells. [Stiehler et al. 2006]. To assess whether advanced-stage OA affects MSCs’ suitability for musculoskeletal regenerative therapy we compared proliferation and differentiation potential of MSCs from osteoarthritic versus healthy donors.

Methods: WOMAC, EQ-5D, Harris Hip Score, extended laboratory scan, and radiological classification of the affected hip joint (OA group only) were performed. Subjects on bone metabolism-affecting medication were excluded from the study. MSCs were isolated from bone marrow aspirates obtained from the pelvic compartments of n=14 advanced-stage osteoarthritic (Kellgren and Lawrence grade 3 or 4, mean age 67±6 years) and n=15 age-matched (61±4 years) healthy donors by gradient-separation and polystyrene adhesion method. MSCs were cultured in basic (DMEM, 10% fetal calf serum), osteogenic, adipogenic, or chondrogenic medium for up to 21 days. For all assays low-passage (<3) MSC populations were used. Proliferation was assessed by total DNA quantification, FACS analysis and CFU-F assay.

Differentiation was proofed by cell staining and by osteogenic (Runx-2, ALP, BSP2), chondrogenic (Sox9, ColIIa, ColX), and adipogenic (PPARγ, FABP4) qRT-PCR marker gene expression analysis. Additionally, osteogenic differentiation was evaluated by cell-specific alkaline phosphatase (ALP) activity assay.

Overall statistical significance was defined as p<0.05 (two-sided) based on all pairwise comparisons . The study was approved by the local ethics review board (protocol #EK203082008).

Results and conclusions: Algofunctional scores of osteoarthritic donors were significantly lower compared to healthy donors (p<0.0001). No significant differences between osteoarthritic and healthy donors concerning the proliferation potential, cell-specific ALP acitivity and differentiation marker gene expression were observed.

We therefore conclude that the regenerative potential of MSCs from osteoarthritic donors is compa-rable to MSCs from healthy donors. These data will help to facilitate the application of autologous cell-based strategies for musculoskeletal tissue regeneration.